NA (NA) NA https://www.ema.europa.eu/en/endpoints-clinical-studies-haematopoietic-growth-factors-mobilisation-autologous-stem-cells#Clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia#https://www.ema.europa.eu/en/clinical-development-medicinal-products-intended-treatment-chronic-primary-immune-thrombocytopenia#https://www.ema.europa.eu/en/use-minimalresidue-disease-endpoint-chronic-lymphocytic-leukaemia-studies#https://www.ema.europa.eu/en/evaluation-anticancer-medicinal-products-man#https://www.ema.europa.eu/en/clinicaldevelopmentmedicinal-products-treatment-autism-spectrum-disorder-asd# https://www.ema.europa.eu/en/clinical-developmentmedicinal-products-intended-treatment-pain#https://www.ema.europa.eu/en/clinical-investigation-medicinal-products-treatment-duchenne-becker-muscular-dystrophy#https://www.ema.europa.eu/en/clinical-investigationmedicinal-products-treatment-multiple-sclerosis#https://www.ema.europa.eu/en/clinical-investigationmedicinal-products-treatment-parkinsons-disease